Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 12Phase 1/2 6Phase NA 3Phase 4 3Phase 2/3 3Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 139Lymphoid 60Other hematologic neoplasm 41Genitourinary 8Gastrointestinal 6Myeloid 5CNS 5Tumor-Agnostic 4Other solid neoplasm 4Dermatologic 4Sarcoma 3Breast 3Thoracic 2Head & Neck 2Gynecologic 1Endocrine 1Classical hematology 1

Conditions

Mesothelioma 2Mesothelioma, Malignant 1

Interventions

pembrolizumab 156Carboplatin 146Cisplatin 129Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 68Docetaxel 61Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33130-nm albumin-bound paclitaxel 26Radiosurgery 25fludarabine 23Ipilimumab 23Irinotecan 21Taxes 20Radiation 20Oxaliplatin 20Magnetic Resonance Spectroscopy 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Dexamethasone × Thoracic × Clear all
NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

NCT00402766 2015-11-18

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

M.D. Anderson Cancer Center

Phase 1 Completed
19 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡